[1]
|
Ding, S.Z., Du, Y.Q., Lu, H., et al. (2022) Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut, 71, 238-253. https://doi.org/10.1136/gutjnl-2021-325630
|
[2]
|
Zhou, X.Z., Lyu, N.H., Zhu, H.Y., et al. (2023) Large-Scale, National, Family-Based Epidemiological Study on Helicobacter pylori Infection in China: The Time to Change Practice for Related Disease Prevention. Gut, 72, 855-869.
https://doi.org/10.1136/gutjnl-2022-328965
|
[3]
|
Choi, I.J., Kook, M.C., Kim, Y.I., et al. (2018) Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. New England Journal of Medicine, 378, 1085-1095. https://doi.org/10.1056/NEJMoa1708423
|
[4]
|
Smyth, E.C., Nilsson, M., Grabsch, H.I., et al. (2020) Gastric Cancer. Lancet, 396, 635-648.
https://doi.org/10.1016/S0140-6736(20)31288-5
|
[5]
|
Malfertheiner, P., Megraud, F., O’morain, C.A., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288
|
[6]
|
Malfertheiner, P., Megraud, F., Rokkas, T., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762. https://doi.org/10.1136/gutjnl-2022-327745
|
[7]
|
袁耀宗. 酸相关性疾病的抑酸标准及抑酸药物选择[J]. 中华消化杂志, 2023, 43(9): 579-582.
|
[8]
|
Shimatani, T., Inoue, M., Kuroiwa, T., et al. (2005) Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 mg Twice Daily Rabeprazole with 20 mg Twice Daily Rabeprazole, 30 mg Twice Daily Lansoprazole, and 20 mg Twice Daily Omeprazole by 24-Hr Intragastric PH-Metry. Digestive Diseases and Sciences, 50, 1202-1206. https://doi.org/10.1007/s10620-005-2760-0
|
[9]
|
Shimatani, T., Inoue, M., Kuroiwa, T., et al. (2006) Ac-id-Suppressive Effects of Rabeprazole, Omeprazole, and Lansoprazole at Reduced and Standard Doses: A Crossover Comparative Study in Homozygous Extensive Metabolizers of Cytochrome P4502C19. Clinical Pharmacology & Therapeutics, 79, 144-152.
https://doi.org/10.1016/j.clpt.2005.09.012
|
[10]
|
Sakurai, Y., Mori, Y., Okamoto, H., et al. (2015) Ac-id-Inhibitory Effects of Vonoprazan 20mg Compared with Esomeprazole 20mg or Rabeprazole 10mg in Healthy Adult Male Subjects—A Randomised Open-Label Cross-Over Study. Alimentary Pharmacology & Therapeutics, 42, 719-730. https://doi.org/10.1111/apt.13325
|
[11]
|
葛均波, 徐永健, 王辰. 内科学[M]. 第九版. 北京: 人民卫生出版社, 2018: 358.
|
[12]
|
Geibel, J.P. (2005) Role of Potassium in Acid Secretion. World Journal of Gastroen-terology, 11, 5259-5265.
https://doi.org/10.3748/wjg.v11.i34.5259
|
[13]
|
何金杰, 程能能. 钾离子竞争性酸阻断剂——伏诺拉生[J]. 中国临床药学杂志, 2019, 28(3): 219-222.
|
[14]
|
Echizen, H. (2016) The First-In-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacoki-netics, 55, 409-418.
https://doi.org/10.1007/s40262-015-0326-7
|
[15]
|
曾琳, 聂刚. 新型抑酸药伏诺拉生根除幽门螺杆菌的研究进展[J]. 中国临床新医学, 2023, 16(11): 1204-1209.
|
[16]
|
Miftahussurur, M., Putra, B.P., Yamaoka, Y. (2020) The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals, 13, Article 276. https://doi.org/10.3390/ph13100276
|
[17]
|
Hori, Y., Matsukawa, J., Takeuchi, T., et al. (2011) A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals. The Journal of Pharmacology and Experimental Therapeutics, 337, 797-804. https://doi.org/10.1124/jpet.111.179556
|
[18]
|
Otake, K., Sakurai, Y., Nishida, H., et al. (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Advances in Therapy, 33, 1140-1157. https://doi.org/10.1007/s12325-016-0345-2
|
[19]
|
Mori, H. and Suzuki, H. (2019) Role of Acid Suppression in Acid-Related Diseases: Proton Pump Inhibitor and Potassium-Competitive Acid Blocker. Journal of Neurogastroenterology and Motility, 25, 6-14.
https://doi.org/10.5056/jnm18139
|
[20]
|
Jenkins, H., Jenkins, R. and Patat, A. (2017) Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clinical Drug Investigation, 37, 311-316. https://doi.org/10.1007/s40261-016-0488-6
|
[21]
|
Jenkins, H., Sakurai, Y., Nishimura, A., et al. (2015) Ran-domised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects. Alimentary Pharmacology & Therapeutics, 41, 636-648. https://doi.org/10.1111/apt.13121
|
[22]
|
Kagami, T., Sahara, S., Ichikawa, H., et al. (2016) Potent Acid Inhibition by Vonoprazan in Comparison with Esomeprazole, with Refer-ence to CYP2C19 Genotype. Alimentary Pharmacology & Therapeutics, 43, 1048-1059.
https://doi.org/10.1111/apt.13588
|
[23]
|
Yang, X.X., Li, Y.Y., Sun, Y.Y., et al. (2018) Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Digestive Diseases and Sciences, 63, 302-311. https://doi.org/10.1007/s10620-017-4866-6
|
[24]
|
Murakami, K., Sakurai, Y., Shiino, M., et al. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1346. https://doi.org/10.1136/gutjnl-2015-311304
|
[25]
|
Rokkas, T., Gisbert, J.P., Malfertheiner, P., et al. (2021) Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-Analysis. Gastroenterology, 161, 495-507.E4.
https://doi.org/10.1053/j.gastro.2021.04.012
|
[26]
|
Li, M., Oshima, T., Horikawa, T., et al. (2018) Systematic Review with Meta-Analysis: Vonoprazan, a Potent Acid Blocker, Is Superior to Proton-Pump Inhibitors for Erad-ication of Clarithromycin-Resistant Strains of Helicobacter pylori. Helicobacter, 23, e12495. https://doi.org/10.1111/hel.12495
|
[27]
|
Bunchorntavakul, C. and Buranathawornsom, A. (2021) Randomized Clinical Trial: 7-Day Vonoprazan-Based versus 14-Day Omeprazole-Based Triple Therapy for Helicobacter pylori. Journal of Gastroenterology and Hepatology, 36, 3308-3313. https://doi.org/10.1111/jgh.15700
|
[28]
|
Hou, X.H., Meng, F.D., Wang, J.B., et al. (2022) Vonoprazan Non-Inferior to Lansoprazole in Treating Duodenal Ulcer and Eradicating Helicobacter pylori in Asian Patients. Journal of Gastroenterology and Hepatology, 37, 1275-1283. https://doi.org/10.1111/jgh.15837
|
[29]
|
Huh, K.Y., Chung, H., Kim, Y.K., et al. (2022) Evaluation of Safety and Pharmacokinetics of Bismuth-Containing Quadruple Therapy with Either Vonoprazan or Lansoprazole for Helicobacter pylori Eradication. British Journal of Clinical Pharmacology, 88, 138-144. https://doi.org/10.1111/bcp.14934
|
[30]
|
Lu, L.F., Wang, Y.J., Ye, J., et al. (2023) Quadruple Therapy with Vonoprazan 20 mg Daily as a First-Line Treatment for Helicobacter pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial. Helicobacter, 28, e12940. https://doi.org/10.1111/hel.12940
|
[31]
|
Suzuki, S., Esaki, M., Kusano, C., et al. (2019) Development of Hel-icobacter pylori Treatment: How Do We Manage Antimicrobial Resistance? World Journal of Gastroenterology, 25, 1907-1912.
https://doi.org/10.3748/wjg.v25.i16.1907
|
[32]
|
Suzuki, S., Gotoda, T., Kusano, C., et al. (2020) Seven-Day Vonoprazan and Low-Dose Amoxicillin Dual Therapy as First-Line Helicobacter pylori Treatment: A Multicentre Randomised Trial in Japan. Gut, 69, 1019-1026.
https://doi.org/10.1136/gutjnl-2019-319954
|
[33]
|
Gotoda, T., Kusano, C., Suzuki, S., et al. (2020) Clinical Impact of Vonoprazan-Based Dual Therapy with Amoxicillin for H. pylori Infection in a Treatment-Naive Cohort of Junior High School Students in Japan. Journal of Gastroenterology, 55, 969-976. https://doi.org/10.1007/s00535-020-01709-4
|
[34]
|
Sue, S., Kondo, M., Sato, T., et al. (2023) Vonoprazan and High-Dose Amoxicillin Dual Therapy for Helicobacter pylori First-Line Eradication: A Single-Arm, Interventional Study. JGH Open, 7, 55-60.
https://doi.org/10.1002/jgh3.12852
|
[35]
|
Lin, Y.M., Xu, H.M., Yun, J.W., et al. (2022) The Efficacy of Vonoprazan Combined with Different Dose Amoxicillin on Eradication of Helicobacter pylori: An Open, Multi-center, Randomized Clinical Study. Annals of Translational Medicine, 10, Article 987. https://doi.org/10.21037/atm-22-4133
|
[36]
|
Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Optimization of Vonoprazan-Amoxicillin Dual Therapy for Eradicating Helicobacter pyloriInfection in China: A Prospective, Randomized Clinical Pilot Study. Helicobacter, 27, e12896.
https://doi.org/10.1111/hel.12896
|
[37]
|
Chey, W.D., Mégraud, F., Laine, L., et al. (2022) Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology, 163, 608-619.
https://doi.org/10.1053/j.gastro.2022.05.055
|
[38]
|
Kang, J., Kim, Y.J., Shim, T.S., et al. (2018) Risk for Car-diovascular Disease in Patients with Nontuberculous Mycobacteria Treated with Macrolide. Journal of Thoracic Disease, 10, 5784-5795. https://doi.org/10.21037/jtd.2018.09.145
|
[39]
|
Horii, T., Suzuki, S., Takano, C., et al. (2021) Lower Impact of Vonoprazan-Amoxicillin Dual Therapy on Gut Microbiota for Helicobacter pylori Erad-ication. Journal of Gastroenterology and Hepatology, 36, 3314-3321.
https://doi.org/10.1111/jgh.15572
|
[40]
|
Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Altered Gut Microbiota and Short-Chain Fatty Acids after Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Frontiers in Cellular and Infection Microbiology, 12, Article 881968. https://doi.org/10.3389/fcimb.2022.881968
|
[41]
|
Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Analysis of Oral Microbiota Alterations Induced by Helicobacter pylori Infection and Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Helicobacter, 27, e12923.
https://doi.org/10.1111/hel.12923
|
[42]
|
Katayama, Y., Toyoda, K., Kusano, Y., et al. (2017) Efficacy of Vonoprazan-Based Second-Line Helicobacter pylori Eradication Therapy in Patients for Whom Vonoprazan-Based First-Line Treatment Failed. Gut, 66, 752-753.
https://doi.org/10.1136/gutjnl-2016-312028
|
[43]
|
Hojo, M., Asaoka, D., Takeda, T., et al. (2020) Randomized Controlled Study on the Effects of Triple Therapy Including Vonoprazan Or Rabeprazole for the Second-Line Treatment of Helicobacter pylori Infection. Therapeutic Advances in Gastroenterology, 13, 1-11. https://doi.org/10.1177/1756284820966247
|
[44]
|
Zhou, L.Y., et al. (2022) Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment. Chinese Journal of Digestion, 42, 745-756.
|
[45]
|
Murakami, K., Sato, R., Okimoto, T., et al. (2006) Effectiveness of Minocycline-Based Triple Therapy for Eradication of Helicobacter pylori Infection. Journal of Gastroenterology and Hepatology, 21, 262-267.
https://doi.org/10.1111/j.1440-1746.2006.04183.x
|
[46]
|
Yang, J.C., Lin, C.J., Wang, H.L., et al. (2015) High-Dose Dual Therapy Is Superior to Standard First-Line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology, 13, 895-905.E5.
https://doi.org/10.1016/j.cgh.2014.10.036
|
[47]
|
Bi, H.X., Chen, X.X., Chen, Y.X., et al. (2022) Efficacy and Safety of High-Dose Esomeprazole-Amoxicillin Dual Therapy for Helicobacter pylori Rescue Treatment: A Mul-ticenter, Prospective, Randomized, Controlled Trial. Chinese Medical Journal, 135, 1707-1715. https://doi.org/10.1097/CM9.0000000000002289
|
[48]
|
Sue, S., Shibata, W., Sasaki, T., et al. (2019) Ran-domized Trial of Vonoprazan-Based versus Proton-Pump Inhibitor-Based Third-Line Triple Therapy with Sitafloxacin for Helicobacter pylori. Journal of Gastroenterology and Hepatology, 34, 686-692. https://doi.org/10.1111/jgh.14456
|
[49]
|
Saito, Y., Konno, K., Sato, M., et al. (2019) Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers, 11, Article 116. https://doi.org/10.3390/cancers11010116
|
[50]
|
Inokuchi, K., Mori, H., Matsuzaki, J., et al. (2022) Efficacy and Safety of Low-Dose Rifabutin-Based 7-Day Triple Therapy as a Third- or Later-Line Helicobacter pylori Eradication Regimen. Helicobacter, 27, e12900.
https://doi.org/10.1111/hel.12900
|
[51]
|
Hirata, Y., Yamada, A., Niikura, R., et al. (2020) Efficacy and Safety of a New Rifabutin-Based Triple Therapy with Vonoprazan for Refractory Helicobacter pyloriInfection: A Pro-spective Single-Arm Study. Helicobacter, 25, e12719.
https://doi.org/10.1111/hel.12719
|
[52]
|
Astruc, B., Jenkins, H. and Jenkins, R. (2017) Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects. Clinical and Translational Science, 10, 208-216.
https://doi.org/10.1111/cts.12452
|
[53]
|
Kakiuchi, T., Matsuo, M., Endo, H., et al. (2023) Efficacy and Safety of Vonoprazan-Based Regimen for Helicobacter pylori Eradication Therapy in Japanese Adolescents: A Prospec-tive Multicenter Study. Journal of Gastroenterology, 58, 196-204. https://doi.org/10.1007/s00535-022-01942-z
|
[54]
|
Sugano, K. (2018) Vonoprazan Fumarate, a Novel Potas-sium-Competitive Acid Blocker, in the Management of Gastroesophageal Reflux Disease: Safety and Clinical Evidence to Date. Therapeutic Advances in Gastroenterology, 11, 1-14. https://doi.org/10.1177/1756283X17745776
|
[55]
|
Saruta, Y., Watanabe, K., Tsuji, T., et al. (2023) Vonoprazan Poses No Additional Risk of Developing Clostridioides difficile Infection Compared to Proton Pump Inhibitors. Journal of Gastroenterology and Hepatology, 38, 940-947.
https://doi.org/10.1111/jgh.16169
|
[56]
|
Miyamoto, S., Matsuno, Y., Kato, M., et al. (2017) Parietal Cell Pro-trusions and Dilated Oxyntic Glands from Use of Vonoprazan. American Journal of Gastroenterology, 112, 1899-1901. https://doi.org/10.1038/ajg.2017.364
|
[57]
|
Yoshizaki, T., Morisawa, T., Fujinami, M., et al. (2021) Propensity Score Matching Analysis: Incidence and Risk Factors for “Stardust” Gastric Mucosa, a Novel Gastric Finding Potentially Induced by Vonoprazan. Alimentary Pharmacology & Therapeutics, 53, 94-102. https://doi.org/10.1111/apt.16151
|